MCID: ADN027
MIFTS: 46

Adenomyosis malady

Categories: Rare diseases

Aliases & Classifications for Adenomyosis

Aliases & Descriptions for Adenomyosis:

Name: Adenomyosis 50
Endometriosis of Uterus 69

Classifications:



Summaries for Adenomyosis

NIH Rare Diseases : 50 adenomyosis is a rare condition that affects the uterus. in affected women, the endometrial tissue (which typically lines the uterus) moves into the outer, muscular walls of the uterus. some women may have no signs or symptoms of the condition. when present, features of the condition include heavy menstrual bleeding, painful menstrual periods, and pelvic pain during intercourse. some women may also develop an adenomyoma, which is a mass or growth within the uterus. the underlying cause of the condition is currently unknown. in general, treatment is based on the signs and symptoms present in each person. forms of birth control that contain progesterone (such as birth control pills or an iud) may decrease heavy bleeding while certain medications can be used to manage pain. in severe cases, a hysterectomy may be recommended. last updated: 3/15/2017

MalaCards based summary : Adenomyosis, also known as endometriosis of uterus, is related to uterine disease and endometriosis of uterus. An important gene associated with Adenomyosis is MMP2 (Matrix Metallopeptidase 2), and among its related pathways/superpathways are GPCR Pathway and Cytokine Signaling in Immune system. The drugs Acetaminophen and Ibuprofen have been mentioned in the context of this disorder. Affiliated tissues include uterus, endothelial and pituitary, and related phenotypes are homeostasis/metabolism and behavior/neurological

Wikipedia : 71 Adenomyosis is a gynecologic medical condition characterized by the abnormal presence of endometrial... more...

Related Diseases for Adenomyosis

Diseases related to Adenomyosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 186)
id Related Disease Score Top Affiliating Genes
1 uterine disease 11.2
2 endometriosis of uterus 11.0
3 endometriosis 10.5
4 bartholin's gland benign neoplasm 10.3 ESR1 PGR
5 cardiovascular organ benign neoplasm 10.3 ESR1 PGR
6 appendix leiomyoma 10.3 ESR1 PGR
7 bronchus adenoma 10.3 ESR1 PGR
8 glioma 10.3 ESR1 PGR
9 ovarian benign neoplasm 10.3 ESR1 PGR
10 plexiform neurofibroma 10.3 ESR1 PGR
11 facio skeletal genital syndrome rippberger type 10.3 MMP2 MMP9
12 paranasal sinus disease 10.3 ESR1 PGR
13 deafness, autosomal recessive 21 10.3 ESR1 PGR
14 leiomyoma 10.3
15 cervical lymphoepithelioma-like carcinoma 10.3 ESR1 PGR
16 acute tricyclic antidepressant poisoning 10.3 MMP2 MMP9
17 histiocytic and dendritic cell cancer 10.3 ESR1 PGR
18 atypical lipomatous tumor 10.3 ESR1 PGR
19 pediatric intraocular retinoblastoma 10.3 ESR1 PGR
20 leukoencephalopathy palmoplantar keratoderma 10.3 MMP2 MMP9
21 congenital disorder of glycosylation, type ic 10.3 ESR1 PGR
22 thymus adenocarcinoma 10.3 MMP2 MMP9
23 her2-receptor negative breast cancer 10.3 ESR1 PGR
24 intestinal perforation 10.3 ESR1 PGR
25 perlman syndrome 10.3 ESR1 PGR
26 nervous system hibernoma 10.3 ESR1 PGR
27 spinal meninges cancer 10.3 MMP2 MMP9
28 neonatal hypoxic and ischemic brain injury 10.3 MMP2 MMP9
29 kidney osteogenic sarcoma 10.3 MMP9 VEGFA
30 bladder adenocarcinoma 10.3 ESR1 PGR
31 anal neuroendocrine tumor 10.3 ESR1 PGR
32 osteogenesis imperfecta 10.3 ESR1 PGR
33 central nervous system adult germ cell tumor 10.2 MMP9 TIMP2
34 poliomyelitis 10.2 ESR1 PGR
35 hepatic vascular disease 10.2 MMP9 VEGFA
36 tinea profunda 10.2 MMP2 MMP9
37 noonan syndrome 4 10.2 MMP1 MMP2
38 adenocarcinoma 10.2
39 gallbladder papillomatosis 10.2 MMP2 PGR VEGFA
40 large cell medulloblastoma 10.2 MMP9 VEGFA
41 adult-onset distal myopathy due to vcp mutation 10.2 MMP1 MMP9
42 diffuse large b-cell lymphoma 10.2 MMP1 MMP9
43 viral meningitis 10.2 MMP2 MMP9
44 fallopian tube carcinosarcoma 10.2 ESR1 PGR VEGFA
45 main bronchus cancer 10.2 PGR VEGFA
46 polyp of corpus uteri 10.2 MMP1 MMP2
47 glycerol kinase deficiency, adult form 10.2 ESR1 PGR VEGFA
48 prostatic adenoma 10.2 ESR1 PGR VEGFA
49 lymphocytic colitis 10.2 MMP2 MMP9
50 vulva basal cell carcinoma 10.2 ESR1 PGR

Graphical network of the top 20 diseases related to Adenomyosis:



Diseases related to Adenomyosis

Symptoms & Phenotypes for Adenomyosis

MGI Mouse Phenotypes related to Adenomyosis:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.2 CDH1 ESR1 MMP1 MMP2 MMP9 NGF
2 behavior/neurological MP:0005386 10.16 ESR1 MMP9 NGF OXTR PGR PRL
3 cardiovascular system MP:0005385 10.15 CDH1 ESR1 MMP2 MMP9 NGF PGR
4 immune system MP:0005387 10.13 CDH1 ESR1 MMP1 MMP2 MMP9 PGR
5 integument MP:0010771 10.06 CDH1 ESR1 MMP9 NGF OXTR PGR
6 endocrine/exocrine gland MP:0005379 10.02 CDH1 ESR1 OXTR PGR PRL PTGS2
7 muscle MP:0005369 9.97 VEGFA ESR1 MMP2 MMP9 NGF OXTR
8 neoplasm MP:0002006 9.97 PGR PRL PTGS2 VEGFA CDH1 ESR1
9 nervous system MP:0003631 9.91 TIMP2 VEGFA ESR1 MMP2 MMP9 NGF
10 no phenotypic analysis MP:0003012 9.7 NGF OXTR PGR PTGS2 VEGFA CDH1
11 normal MP:0002873 9.61 CDH1 ESR1 MMP2 NGF OXTR PGR
12 reproductive system MP:0005389 9.23 CDH1 ESR1 MMP9 OXTR PGR PRL

Drugs & Therapeutics for Adenomyosis

Drugs for Adenomyosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4 103-90-2 1983
2
Ibuprofen Approved Phase 4 15687-27-1 3672
3
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
4 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
5 Analgesics Phase 4,Phase 3
6 Analgesics, Non-Narcotic Phase 4
7 Anti-Inflammatory Agents Phase 4
8 Anti-Inflammatory Agents, Non-Steroidal Phase 4
9 Antipyretics Phase 4
10 Antirheumatic Agents Phase 4
11 Cyclooxygenase Inhibitors Phase 4
12 Ketorolac Tromethamine Phase 4
13 Ramosetron Approved Phase 3 132036-88-5
14
Goserelin Approved Phase 2, Phase 3 65807-02-5 47725 5311128
15
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
16 Antiemetics Phase 3
17 Autonomic Agents Phase 3
18 Gastrointestinal Agents Phase 3
19 Neurotransmitter Agents Phase 3,Phase 1
20
Serotonin Phase 3 50-67-9 5202
21 Serotonin Agents Phase 3
22 Serotonin Antagonists Phase 3
23 Hormone Antagonists Phase 2, Phase 3,Phase 1,Early Phase 1
24 Hormones Phase 2, Phase 3,Phase 1,Early Phase 1
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1,Early Phase 1
26 Antineoplastic Agents, Hormonal Phase 2, Phase 3
27 Aromatase Inhibitors Phase 2, Phase 3
28 Estrogen Antagonists Phase 2, Phase 3
29 Estrogens Phase 2, Phase 3,Early Phase 1
30
Lactitol Phase 2, Phase 3 585-86-4 3871
31 Steroid Synthesis Inhibitors Phase 2, Phase 3
32 Micronutrients Phase 3
33 Trace Elements Phase 3
34
Levonorgestrel Approved, Investigational Phase 2,Early Phase 1 797-63-7, 17489-40-6 13109
35
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
36
Ropivacaine Approved Phase 2 84057-95-4 71273 175805
37 Contraceptive Agents Phase 2,Early Phase 1
38 Contraceptives, Oral Phase 2,Early Phase 1
39 Contraceptives, Oral, Combined Phase 2,Early Phase 1
40 Anesthetics Phase 2
41 Anesthetics, Local Phase 2
42 Anti-Arrhythmia Agents Phase 2
43 Central Nervous System Depressants Phase 2
44 Diuretics, Potassium Sparing Phase 2,Early Phase 1
45 Sodium Channel Blockers Phase 2
46
Bromocriptine Approved, Investigational Phase 1 25614-03-3 31101
47
Dopamine Approved Phase 1 51-61-6, 62-31-7 681
48 Antiparkinson Agents Phase 1
49 Dopamine Agents Phase 1
50 Dopamine agonists Phase 1

Interventional clinical trials:

(show all 49)
id Name Status NCT ID Phase
1 Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure Completed NCT02227316 Phase 4
2 Surgical Success After Laparoscopic vs Abdominal Hysterectomy Recruiting NCT01793584 Phase 4
3 Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy Unknown status NCT01483417 Phase 3
4 The Use of Doppler to Diagnose Myometrial Masses Unknown status NCT01833871 Phase 2, Phase 3
5 Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01048931 Phase 3
6 Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3
7 Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis Completed NCT01218581 Phase 2, Phase 3
8 Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy Completed NCT01064128 Phase 3
9 Uterine Artery Embolization for Symptomatic Fibroids Completed NCT00354471 Phase 3
10 Efficacy of Trace Elements in the Treatment of Endometriosis: a Pilot Study Active, not recruiting NCT02437175 Phase 3
11 LNG-IUS for Treatment of Dysmenorrhea Unknown status NCT01601366 Phase 2
12 Tactile Electrosurgical Ablation in Cases of Dysfunctional Uterine Bleeding Completed NCT02248194 Phase 2
13 Adenomyosis and Ulipristal Acetate Recruiting NCT02587000 Phase 2
14 Superior Hypogastric Nerve Block for Pain Control Post-UFE Recruiting NCT02270255 Phase 2
15 Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis Withdrawn NCT02794467 Phase 2
16 Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? Completed NCT02192606 Phase 1
17 Vaginal Bromocriptine for Treatment of Adenomyosis Active, not recruiting NCT01821001 Phase 1
18 Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis Unknown status NCT01259180
19 Evaluation of Endometrial Stromal Cell Apoptosis in Adenomyosis Unknown status NCT00172588
20 Proliferation of Endometrial Stromal Cells in Adenomyosis Unknown status NCT00173212
21 Health-Related QoL Among Women Receiving Hysterectomy in NTUH Unknown status NCT00155870
22 Progestin Treatment for Endometrial Stromal Cells in Adenomyosis Unknown status NCT00155051
23 To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01564602
24 The Impact of Gynecological Surgery on Ovarian Function in Women of Reproductive Age: Postoperative Changes of Serum Anti-Müllerian Hormone (AMH) Unknown status NCT00928044
25 Long Term Outcomes Following Total Laparoscopic Hysterectomy and Laparoscopic Supracervical Hysterectomy Unknown status NCT01289314
26 Histopathological Diagnosis of Adenomyosis Completed NCT02340533
27 Norwegian Adenomyosis Study I Completed NCT02201719
28 Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis Completed NCT03027648
29 Levonorgestrel Intrauterine System and Adenomyosis Completed NCT03104309
30 New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma Completed NCT02997787
31 Use of Dexamethasone in Uterine Artery Embolization Completed NCT02056717
32 Use of the Enseal Intrument for Laparoscopic Supracervical Hysterectomy Completed NCT01806012
33 AMH Levels Change During Treatment With GnRh Agonist Completed NCT02086279
34 Electronic Catheter Stethoscope Completed NCT01463462
35 Sonohysterography , 3D Ultrasonography and Hysteroscopy in Assessment of Uterine Factor in Cases of Female Infertility Completed NCT02399501
36 The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms Recruiting NCT02495311
37 Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Recruiting NCT03037944 Early Phase 1
38 Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU) Recruiting NCT02914704
39 Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy Recruiting NCT02086344
40 Effect of Shorten Gonadotropin-releasing Hormone Agonist Therapy on the Outcome of in Vitro Fertilization-Embryo Transfer in Patients With Endometriosis Recruiting NCT03006406
41 Effect of Salpingectomy During Conservative Hysterectomy Recruiting NCT01628432
42 Norwegian Adenomyosis Study II: Gene Expression Profiling of Adenomyosis Active, not recruiting NCT02197923
43 Norwegian Adenomyosis Study III: Peristalsis Active, not recruiting NCT02197936
44 What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Active, not recruiting NCT01992718 Early Phase 1
45 Functional Brain Imaging and Psychological Testing in Women With Chronic Pelvic Pain Active, not recruiting NCT02160483
46 High-intensity Focused Ultrasound in Treatment of Uterine Adenomyosis Enrolling by invitation NCT02954757
47 Diagnostic Accuracy of Ultrasound for Adenomyosis, Development of Scoring System and Correlation With Various Pelvic Pathologies: a Prospective Study. Not yet recruiting NCT03120078
48 Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Not yet recruiting NCT02556411
49 Acceptability and Tolerance of Hysteroscopy and Hysterosonography in Consultation Not yet recruiting NCT03121560

Search NIH Clinical Center for Adenomyosis

Genetic Tests for Adenomyosis

Anatomical Context for Adenomyosis

MalaCards organs/tissues related to Adenomyosis:

39
Uterus, Endothelial, Pituitary, Smooth Muscle, Monocytes, Breast, Cervix

Publications for Adenomyosis

Articles related to Adenomyosis:

(show top 50) (show all 657)
id Title Authors Year
1
Ultrasound-guided transcervical radiofrequency ablation for symptomatic uterine adenomyosis. ( 27792415 )
2017
2
Serum Osteopontin Levels Are Decreased in Focal Adenomyosis. ( 27678100 )
2017
3
Downregulation of DNA methyltransferase 3 alpha promotes cell proliferation and invasion of ectopic endometrial stromal cells in adenomyosis. ( 27986572 )
2017
4
Safety of ultrasound-guided high-intensity focused ultrasound ablation for diffuse adenomyosis: A retrospective cohort study. ( 28069193 )
2017
5
Treatment strategies for pelvic pain associated with adenomyosis. ( 27759444 )
2016
6
The Role of Adenomyosis in the Pathogenesis of Preeclampsia. ( 27582582 )
2016
7
Dysfunctional coagulation and fibrinolysis systems due to adenomyosis is a possible cause of thrombosis and menorrhagia. ( 27543913 )
2016
8
UTERINE ADENOMYOSIS AND AN ENDOMETRIAL POLYP IN A ROCK HYRAX (PROCAVIA CAPENSIS). ( 28080921 )
2016
9
The role of pathologic evaluation of endometrial ablation resections in predicting ablation failure and adenomyosis in hysterectomy. ( 27461823 )
2016
10
Anti-platelet therapy holds promises in treating adenomyosis: experimental evidence. ( 27724926 )
2016
11
Variables associated with vaginal discharge after ultrasound-guided percutaneous microwave ablation for adenomyosis. ( 27087631 )
2016
12
Proangiogenic features in chronic pelvic pain caused by adenomyosis. ( 27759451 )
2016
13
Clinical Predictors of Long-term Success in Ultrasound-guided High-intensity Focused Ultrasound Ablation Treatment for Adenomyosis: A Retrospective Study. ( 26817877 )
2016
14
Correlation between Cyr61 expression and clinicopathologic parameters in adenomyosis. ( 27644084 )
2016
15
Expression of Inflammatory and Neurogenic Mediators in Adenomyosis: A Pathogenetic Role. ( 27440813 )
2016
16
Decreased Endometrial Expression of Leukemia Inhibitory Factor Receptor Disrupts the STAT3 Signaling in Adenomyosis During the Implantation Window. ( 27903796 )
2016
17
Clinicopathological Characteristics of Ten Patients with Atypical Glandular Hyperplasia Transformation of Adenomyosis. ( 26831242 )
2016
18
Coexistence of adenomyosis and endometrioid endometrial cancer: Role in surgical guidance and prognosis estimation. ( 26893721 )
2016
19
Involvement of NADPH oxidase and NF-I_B activation in CXCL1 induction by vascular endothelial growth factor in human endometrial epithelial cells of patients with adenomyosis. ( 27665197 )
2016
20
The effect of adenomyosis on the outcomes of laparoscopic hysterectomy. ( 27651723 )
2016
21
Adenomyosis and Abnormal Uterine Bleeding (AUB-A)-Pathogenesis, diagnosis, and management. ( 27810281 )
2016
22
The evaluation of uterine artery embolization as a nonsurgical treatment option for adenomyosis. ( 26868068 )
2016
23
Multiple Cerebral Infarctions in a Patient with Adenomyosis on Hormone Replacement Therapy: A Case Report. ( 27520610 )
2016
24
Value of ultrasound shear wave elastography in the diagnosis of adenomyosis. ( 27847535 )
2016
25
Outcomes in Adenomyosis Treated with Uterine Artery Embolization Are Associated with Lesion Vascularity: A Long-Term Follow-Up Study of 252 Cases. ( 27806072 )
2016
26
Down-regulation of tumor suppressor PDCD4 expression in endometrium of adenomyosis patients. ( 27765271 )
2016
27
Long-Term Efficacy of Laparoscopic or Robotic Adenomyomectomy with or without Medical Treatment for Severely Symptomatic Adenomyosis. ( 26894488 )
2016
28
The Impact of Adenomyosis on Women's Fertility. ( 27640610 )
2016
29
Developmental Toxicant Exposure Is Associated with Transgenerational Adenomyosis in a Murine Model. ( 27535957 )
2016
30
A rapidly growing adenomyosis associated with preterm delivery and postpartum abscess formation. ( 27590398 )
2016
31
LPS/TLR4-mediated stromal cells acquire an invasive phenotype and are implicated in the pathogenesis of adenomyosis. ( 26898650 )
2016
32
Role of benign ovarian cysts in the development of adenomyosis. ( 27570851 )
2016
33
Effect of matrix metalloproteinase promoter polymorphisms on endometriosis and adenomyosis risk: evidence from a meta-analysis. ( 27659332 )
2016
34
Optimizing the Histological Diagnosis of Adenomyosis Using in vitro Three-Dimensional Ultrasonography. ( 27002642 )
2016
35
Dienogest reduces proliferation, NGF expression and nerve fiber density in human adenomyosis. ( 27865118 )
2016
36
Increased expression of nuclear factor kappa-B p65 subunit in adenomyosis. ( 27004203 )
2016
37
Temporarily Blocking the Uterine Artery to Dig Out a Diffused Adenomyosis Lesion Treated Laparoscopically. ( 27702702 )
2016
38
Estradiol Reduces Connexin43 Gap Junctions in the Uterus during Adenomyosis in Cows. ( 27760016 )
2016
39
Spontaneous conception and two successful pregnancies in patient who underwent conservative surgical management of diffuse uterine adenomyosis. ( 27153393 )
2016
40
Monochorionic twin delivery after conservative surgical treatment of a patient with severe diffuse uterine adenomyosis without uterine rupture. ( 27462599 )
2016
41
Live birth in a woman with recurrent implantation failure and adenomyosis following transfer of refrozen-warmed embryos. ( 27689042 )
2016
42
Incidence and Estimated Prevalence of Endometriosis and Adenomyosis in Northeast Italy: A Data Linkage Study. ( 27101396 )
2016
43
Relationship between uterine volume and discontinuation of treatment with levonorgestrel-releasing intrauterine devices in patients with adenomyosis. ( 27155971 )
2016
44
Expression of GRIM-19 inA adenomyosis and its possible roleA in pathogenesis. ( 26769301 )
2016
45
Prolactin role in the bovine uterus during adenomyosis. ( 27591979 )
2016
46
Increased expression of Talin1 in the eutopic and ectopic endometria of women with adenomyosis. ( 26759065 )
2016
47
Adenomyosis in infertile women: prevalence and the role of 3D ultrasound as a marker of severity of the disease. ( 27645154 )
2016
48
Expression of Potassium Channels in Uterine Smooth Muscle Cells from Patients with Adenomyosis. ( 26830992 )
2016
49
Adenomyosis: What the Patient Needs. ( 26772777 )
2016
50
Intravoxel incoherent motion diffusion-weighted imaging in differentiating uterine fibroid from focal adenomyosis: initial results. ( 26759748 )
2016

Variations for Adenomyosis

Expression for Adenomyosis

Search GEO for disease gene expression data for Adenomyosis.

Pathways for Adenomyosis

Pathways related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 33)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.58 ESR1 MMP1 MMP2 MMP9 NGF PTGS2
2
Show member pathways
13.21 MMP1 MMP2 MMP9 PRL PTGS2 VEGFA
3
Show member pathways
12.86 CDH1 ESR1 MMP2 MMP9 PGR VEGFA
4
Show member pathways
12.69 ESR1 MMP2 MMP9 NGF VEGFA
5
Show member pathways
12.68 CDH1 ESR1 NGF PTGS2 VEGFA
6
Show member pathways
12.62 CDH1 MMP1 MMP2 MMP9 TIMP2
7 12.4 CDH1 MMP1 MMP2 MMP9 PTGS2 VEGFA
8 12.19 ESR1 MMP2 MMP9 VEGFA
9 12.02 CDH1 ESR1 MMP1 VEGFA
10 11.97 MMP2 MMP9 VEGFA
11 11.85 CDH1 MMP2 MMP9
12
Show member pathways
11.84 ESR1 PGR PRL
13
Show member pathways
11.75 MMP1 MMP2 MMP9 TIMP2
14 11.71 MMP1 MMP2 MMP9 PTGS2 VEGFA
15 11.69 CDH1 MMP2 MMP9
16 11.67 MMP2 MMP9 PTGS2 TIMP2
17 11.65 CDH1 MMP1 MMP2 MMP9 PTGS2 VEGFA
18 11.54 MMP9 PTGS2 VEGFA
19 11.46 MMP1 PTGS2 VEGFA
20 11.45 MMP1 MMP2 MMP9 TIMP2
21 11.42 ESR1 PTGS2 VEGFA
22 11.42 CDH1 MMP1 MMP2 MMP9 VEGFA
23 11.31 MMP1 MMP9 TIMP2
24 11.22 MMP1 MMP2 MMP9
25 11.09 ESR1 MMP2 MMP9
26 11.07 MMP2 MMP9
27 11.05 MMP9 TIMP2
28 11.03 MMP9 TIMP2 VEGFA
29 10.97 MMP1 MMP2
30 10.92 MMP1 VEGFA
31 10.87 MMP1 MMP9
32
Show member pathways
10.82 MMP1 MMP2 MMP9 PTGS2 VEGFA
33 10.78 MMP1 PTGS2 VEGFA

GO Terms for Adenomyosis

Cellular components related to Adenomyosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 CDH1 MMP1 MMP2 MMP9 NGF PRL
2 extracellular matrix GO:0031012 9.46 MMP1 MMP2 MMP9 TIMP2
3 proteinaceous extracellular matrix GO:0005578 9.02 MMP1 MMP2 MMP9 TIMP2 VEGFA

Biological processes related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 response to organic cyclic compound GO:0014070 9.7 OXTR PRL PTGS2
2 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.61 NGF PTGS2 VEGFA
3 collagen catabolic process GO:0030574 9.58 MMP1 MMP2 MMP9
4 endodermal cell differentiation GO:0035987 9.55 MMP2 MMP9
5 response to drug GO:0042493 9.55 CDH1 OXTR PRL PTGS2 TIMP2
6 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.54 OXTR PTGS2
7 response to cytokine GO:0034097 9.54 OXTR PTGS2 TIMP2
8 mammary gland alveolus development GO:0060749 9.51 ESR1 VEGFA
9 embryo implantation GO:0007566 9.5 MMP2 MMP9 PTGS2
10 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.49 MMP2 MMP9
11 macrophage differentiation GO:0030225 9.48 MMP9 VEGFA
12 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.46 PTGS2 VEGFA
13 lactation GO:0007595 9.43 OXTR PRL VEGFA
14 response to estradiol GO:0032355 9.26 ESR1 OXTR PRL PTGS2
15 extracellular matrix disassembly GO:0022617 9.02 CDH1 MMP1 MMP2 MMP9 TIMP2

Molecular functions related to Adenomyosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 metallopeptidase activity GO:0008237 9.33 MMP1 MMP2 MMP9
2 steroid binding GO:0005496 9.26 ESR1 PGR
3 metalloendopeptidase inhibitor activity GO:0008191 8.96 NGF TIMP2
4 metalloendopeptidase activity GO:0004222 8.8 MMP1 MMP2 MMP9

Sources for Adenomyosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....